DG

Dr. Geoffrey Lynn

Chief Scientific Officer

Barinthus Biotherapeutics

Barinthus Biotherapeutics Pipeline

DrugIndicationPhase
VTP-300Chronic Hepatitis BPhase 1b/2a
VTP-200Low-grade HPV-related Cervical LesionsPhase 1b/2
SNAP-based ProgramsUndisclosed Autoimmune/Inflammatory IndicationsPreclinical